Literature DB >> 18855118

Sensory-motor polyneuropathy occurring in variant maple syrup urine disease.

S Harty1, M D King, B McCoy, D Costigan, E P Treacy.   

Abstract

Maple syrup urine disease (MSUD; OMIM 248600) results from an inherited deficiency of the branched-chain ketoacid dehydrogenase (BCKD) complex. Approximately 20% of patients with BCKD deficiency are non-classic variants of MSUD with differing clinical severity. Outcomes for this cohort are generally favourable; episodes of metabolic decompensation do not appear to correlate with adverse events if acute management is promptly provided. A case of predominantly axonal sensory-motor neuropathy following metabolic decompensation which persisted for a number of months is presented in an adolescent girl with variant (intermediate type) MSUD. EMG and nerve conduction studies suggested a pre-existent asymptomatic chronic neuropathy, exacerbated by the acute decompensation. Peak leucine concentration at decompensation was 1083 μmol/L. The patient had laboratory signs of secondary mitochondrial respiratory chain dysfunction at presentation. She had been on a moderate dose of thiamine prior to decompensation; thiamine and pyridoxine blood concentrations were normal. This, to our knowledge, is the first report of a neuropathy presenting in a patient with a decompensation of variant MSUD. We propose that this presentation resembles the intermittent neuropathy observed in pyruvate dehydrogenase deficiency and may reflect secondary inhibition of pyruvate dehydrogenase activity by MSUD metabolites.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18855118     DOI: 10.1007/s10545-008-0751-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  8 in total

1.  Interrelation between the metabolism of L-isoleucine and L-allo-isoleucine in patients with maple syrup urine disease.

Authors:  U Wendel; U Langenbeck; J W Seakins
Journal:  Pediatr Res       Date:  1989-01       Impact factor: 3.756

2.  Variant maple syrup urine disease (MSUD)--the entire spectrum.

Authors:  E Simon; N Flaschker; P Schadewaldt; U Langenbeck; U Wendel
Journal:  J Inherit Metab Dis       Date:  2006-10-25       Impact factor: 4.982

3.  Oxidation of branched chain amino acids by isolated hearts and diaphragms of the rat. The effect of fatty acids, glucose, and pyruvate respiration.

Authors:  M G Buse; J F Biggers; K H Friderici; J F Buse
Journal:  J Biol Chem       Date:  1972-12-25       Impact factor: 5.157

4.  Acute axonal neuropathy in maple syrup urine disease.

Authors:  K A Kleopa; D M Raizen; C A Friedrich; M J Brown; S J Bird
Journal:  Muscle Nerve       Date:  2001-02       Impact factor: 3.217

5.  Is demyelination a feature of maple syrup urine disease?

Authors:  K Müller; T Kahn; U Wendel
Journal:  Pediatr Neurol       Date:  1993 Sep-Oct       Impact factor: 3.372

6.  Inhibition of brain energy metabolism by the alpha-keto acids accumulating in maple syrup urine disease.

Authors:  Angela M Sgaravatti; Rafael B Rosa; Patrícia F Schuck; César A J Ribeiro; Clóvis M D Wannmacher; Angela T S Wyse; Carlos S Dutra-Filho; Moacir Wajner
Journal:  Biochim Biophys Acta       Date:  2003-11-20

7.  Intermittent peripheral weakness as the presenting feature of pyruvate dehydrogenase deficiency.

Authors:  Francois-G Debray; Marie Lambert; Michel Vanasse; Jean-Claude Decarie; Jessie Cameron; Valeriy Levandovskiy; Brian H Robinson; Grant A Mitchell
Journal:  Eur J Pediatr       Date:  2006-03-22       Impact factor: 3.183

8.  Inhibition of brain energy metabolism by the branched-chain amino acids accumulating in maple syrup urine disease.

Authors:  César A Ribeiro; Angela M Sgaravatti; Rafael B Rosa; Patrícia F Schuck; Vanessa Grando; Anna L Schmidt; Gustavo C Ferreira; Marcos L S Perry; Carlos S Dutra-Filho; Moacir Wajner
Journal:  Neurochem Res       Date:  2007-08-08       Impact factor: 3.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.